Navigation Links
Researchers discover patterns of genes associated with timing of breast cancer recurrences
Date:12/6/2011

SAN ANTONIO -- An international research team led by Georgetown Lombardi Comprehensive Cancer Center has found biological differences in hormone-receptor positive breast cancer that are linked to the timing of recurrence despite endocrine therapy.

They say their findings, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, may help oncologists find ways to individualize systemic therapy to delay or prevent recurrences, and to avoid excessive treatment of patients who will never recur.

"We found that, at the time of diagnosis, there are clear biological differences within the supposedly uniform group of hormone receptor positive breast cancers, and these differences distinguish subtypes relative to the time at which they recur," says Minetta Liu, M.D., director of translational breast cancer research at Georgetown Lombardi Comprehensive Cancer Center.

"We need to exploit these differences and use our data to figure out what drives a tumor to never metastasize. Then we will try to manipulate the cancers that are programmed to recur to act like that of the non-recurrences," she says.

Tamoxifen is credited with saving the lives of thousands of women with estrogen receptor-positive (ER+) breast cancer, which accounts for two-thirds of all diagnoses of invasive breast cancer in the United States. As the world's leading breast cancer treatment and prevention drug, tamoxifen can stave off cancer recurrences for more than 10 years in some patients, but for others, the cancer returns much earlier.

To determine why some ER+ cancers treated with tamoxifen recur earlier rather than later, if at all, Liu and her Georgetown team collaborated with researchers at the University of Edinburgh and with engineers at Virginia Tech.

The Scottish collaborators shared high quality tumor biopsies collected from patients with different stages of breast cancer before they had started tamoxifen therapy. Critical clinical information was available to determine whether or not patients developed metastatic disease, and when the recurrence (if any) was found. The samples were processed and analyzed at Georgetown. Then scientists at Virginia Tech examined the gene expression patterns generated from the tumor biopsies relative to the known clinical outcomes to develop a predictive model of early, late or no disease recurrence.

The final analysis revealed distinct patterns in cancers that recurred early (up to three years from diagnosis) or late (more than ten years from diagnosis). Liu says that some of the genes that were identified were "expected and reassuring," but others were "unexpected and novel." Work is ongoing to validate selected genes as biological drivers of metastasis.

"Endocrine therapy and chemotherapy are not without toxicity," Liu says. "The ability to predict which patients will recur early in their treatment course can lead to more appropriate recommendations for adjuvant chemotherapy. It might also identify those women who would benefit most from studies using investigational agents to enhance the effects of tamoxifen or aromatase inhibitors."
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia
2. Moffitt researchers will be strong participants in American Society of Hematology meeting
3. Moffitt Cancer Center researchers find MK1775 active against sarcomas
4. MU researchers recommend exercise for breast cancer survivors, lymphedema patients
5. NSF awards University of Arizona researchers $530,000 for development of new spectral imager
6. Cleveland researchers find possible breakthrough to relieve pain following spinal cord injury
7. Researchers examine role of inflammatory mechanisms in a healing heart
8. WSU researchers use a 3D printer to make bone-like material
9. Presumed consent not answer to solving organ shortage in US, researchers say
10. Researchers validate preclinical effectiveness of TB drug target
11. Researchers surprised to find fatty liver disease poses no excess risk for death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... In today’s world, homeowners face ... the market, it is easy to start feeling frustrated and confused. To help ... complimentary security consultation. , Home Security Hardware Choices, There are innumerable choices for ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has ... for every household and family to know all about it for optimal health. Wanting ... the release of “ Detox, Digestive and Wellness Solutions ” (published by Balboa Press ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one of ... of Plastic Surgeons. Some patients want to make a change in the appearance of ... their breathing ability. The team at usrhinoplasty.org is expanding its article database ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the further expansion of its eHealth App xChange™, providing clinical researchers more ... Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical trials ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 2017 Cadence Design Systems, Inc. (NASDAQ: ... ® Fusion F1 DSP is part of the latest ... licensable IP targets SoCs designed for battery-powered sensor nodes used ... the Fusion F1 DSP both to implement the IEEE 802.11ah ... audio identification and sensor fusion on a single DSP. Customers ...
(Date:2/21/2017)... and Markets has announced the addition of the "Liver Cirrhosis Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... the following questions: What are the key drugs ... in the Global Liver Cirrhosis market? What are the ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Strategies - 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and ... Rosacea market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Rosacea market? ...
Breaking Medicine Technology: